This clears the way for Medicare and other insurance plans to begin covering the treatment.
WASHINGTON -- U.S. officials granted full approval to a closely watched Alzheimer's drug on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease.
The FDA confirmed those results by reviewing data from a larger, 1,800-patient study in which the drug slowed memory and thinking decline by about five months in those who got the treatment, compared to those who got a dummy drug. by signing up you agree to our terms of service The process of converting a drug to full FDA approval usually attracts little attention. But Alzheimer's patients and advocates have been lobbying the federal government for months after Medicare officials announced last year they wouldn't pay for routine use of Leqembi until it received FDA's full approval.
Medicare administrator, Chiquita Brooks-LaSure, said in a statement Thursday the program will begin paying for the drug now that it has full FDA approval. But the government is also setting extra requirements, including enrollment in a federal registry to track the drug's real-world safety and effectiveness.
Hospitals and medical clinics have cautioned that it may take time to get people started on the drug.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverageLeqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
Leer más »
FDA Approves Leqembi, Extending Alzheimer’s Treatment to More PatientsThe FDA granted full approval to Alzheimer's drug Leqembi, allowing Medicare enrollees to get fully covered treatment with the drug if they qualify and agree to report data to a registry
Leer más »
Alzheimer’s drug Leqembi granted full FDA approvalUPDATE: U.S. officials granted full approval to a closely watched Alzheimer’s drug on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease.
Leer más »
Alzheimer’s drug Leqembi receives full FDA approvalThe Food and Drug Administration endorsed the IV drug, Leqembi, for patients with mild dementia and other symptoms caused by early Alzheimer’s disease. It’s the first medicine that’s been convincingly shown to modestly slow Alzheimer’s cognitive decline.
Leer más »
FDA Approves Promising New Alzheimer’s Drug LeqembiNot only is it the first Alzheimer’s antibody treatment to get full FDA approval, it’s also the first that will be broadly covered by Medicare.
Leer más »
FDA approves Alzheimer’s treatment Leqembi, clearing the way for Medicare coverageDespite Medicare coverage, drug may remain out of reach for many patients, policy experts say
Leer más »